We previously constructed OBP-301 (Telomelysin, a telomerase-specific replication-competent adenovirus with human telomerase reverse transcriptase (hTERT) promoter), which showed a strong anticancer effect by inducing cell lysis of human non-small cell lung cancer and colorectal cancer cells. To investigate the utility of OBP-301 for prostate cancer treatment, we herein evaluate the cell killing and antitumor effects. First, in vitro hTERT-specific adenovirus transduction in human prostate cancer cells (LNCaP, PC3, DU145) was confirmed using OBP-401 (Telomelysin-green fluorescent protein (GFP)). There was no detectable GFP transduction in the human prostate normal cells (PrEC, PrSC). Consistently, the cell-killing effect of OBP-301 was observed only in the cancer cells. Second, using an in vivo subcutaneous LNCaP tumor model in nude mice, we demonstrated that three intratumoral OBP-301 injections (10 7 PFU per tumor Â 3 days) were sufficient to eradicate the detectable LNCaP prostate tumor. We also demonstrated that the ispilateral treatment with OBP-301 significantly suppressed contralateral LNCaP tumor growth in both sides of the tumor model. Histological and immunohistochemical analyses revealed diffuse oncolytic degeneration and adenoviral E1A protein expression in both sides of the tumors. Therefore, in situ OBP-301 administration could be a promising therapeutic strategy against prostate cancer and its metastatic lesions.
Introduction
Prostate cancer has become one of the major causes of male death in the United States, where it is the second cause of cancer death in males. 1 In spite of surgical treatment, androgen deprivation and radiation therapy, disease progression and metastasis still occur in most cases. Therefore, novel and effective therapies are urgently needed for prostate cancer disease.
One of the most innovative approaches for prostate cancer treatment is gene therapy. 2 For example, the adenovirus encoding the HSV-tk gene has already been applied in prostate cancer patients and produced clinical improvements to some extent. 3 However, it has also been reported that adenovirus-mediated cancer gene therapy has some limitations regarding the virus potency to accomplish a radical cure. 4 Currently, to overcome the shortcomings of cancer gene therapy, many efforts to achieve better and stronger gene transfer have been focused on the vector design.
Telomerase is a rib nucleoprotein complex responsible for the complete replication of chromosomal ends, whose activation is considered to be a crucial step not only in cell proliferation but also in carcinogenesis. [5] [6] [7] [8] Previous studies have demonstrated a highly activated telomerase activity in more than 85% of human cancers, 6 but in few normal somatic cells. 7 Human telomerase reverse transcriptase (hTERT) positively regulates telomerase at the transcriptional level and also shows high activities selectively in growing neoplastic tissues and cells. [5] [6] [7] [8] Therefore, it seems reasonable to use an hTERT promoter as a cancer-specific promoter. We previously developed a unique oncolytic strategy using the replicative capacity of adenovirus by driving the E1 gene with an hTERT promoter.
9-14 OBP-301 (Telomelysin), containing the newly innovative adenovirus system, has been reported to induce cell killing of human non-small cell lung cancer and colorectal cancer. 9 Cancer-selective replication-competent oncolytic adenoviruses have been reported to possess potency that, when injected intratumorally, they replicated within tumors, spread into the blood stream and then replicated in distant tumor sites. 9, 14 It is also expected that the cancertargeted replication-competent adenoviruses could achieve significant tumor growth inhibition in distant tumor sites, such as metastatic lesions, as well as in the injected primary tumor. We herein confirm the robust antitumor effects of intratumoral OBP-301 injections not only in the treated prostate tumor in nude mice but also in the contralateral distant tumor, and highlight its therapeutic potentials for clinical use.
Materials and methods

Cell and cell cultures
The human prostate cancer cell lines LNCaP, PC3 and DU145 were provided by American Type Culture Collection (Rockville, MD). The LNCaP cells were maintained in RPMI-1640 medium and supplemented with 10% fetal bovine serum. HAM'S F-12K and minimum essential medium were used for PC3 and DU145 culture medium, supplemented in the same fashion. The cells were cultured in 100-cm 2 flasks. Normal human prostate epithelial cells (PrEC) and stromal cells (PrSC) were purchased from Cambrex (Baltimore, MD) and cultivated using medium recommended by the supplier.
Real-time reverse transcription polymerase chain reaction RNeasy (QIAGEN GmbH, Hilden, Germany) was used for isolation of total RNA from the cells. The hTERT quantification was carried out by PCR amplification using a commercial kit (Roche Diagnostics, Indianapolis, IN), as previously described. 9 Approximately 100 mg of total RNA was used for this experiment.
Recombinant adenoviruses
We previously constructed OBP-301, in which the hTERT promoter element drives the expression of the E1A and E1B genes linked with an internal ribosome entry site. 9, 10 Replication-selective OBP-401 (Telomelysin-green fluorescent protein (Telomelysin-GFP)) containing GFP cDNA under the control of a cytomegalovirus promoter and replication-deficient adenoviral vector containing bgalactosidase cDNA (Ad-LacZ) were also constructed previously. [12] [13] [14] These viruses were purified by CsCl 2 stepgradient ultracentrifugation followed by CsCl 2 lineargradient ultracentrifugation and used in this study. The determination of virus particle titer and infectious titer was accomplished spectrophotometrically, as previously described. 13 In vitro transduction assay Human prostate cancer (LNCaP, PC3, DU145) and normal (PrEC, PrSC) cells were cultured in a four-well slide (5000 cells per well) and were infected with OBP-401 at 100 multiplicity of infection (MOI) for 2 h. The virus was washed away and fresh media was added in the well. After 4, 8, 12 and 24 h, the percentage of fluorescent cells was calculated under fluorescence microscopy.
In vitro cell killing assay The cancer and normal cells were seeded on a 96-well plate at 1000 cells per well. After 24 h incubation, OBP-301 was added at MOIs 0.1, 1 and 10. The in vitro cellkilling effect was analyzed by determining the cell viability at the indicated time points, using a Cell Proliferation Kit (Roche Diagnostics) according to the manufacturer's instructions.
Animals
Adult male BALB/C nu/nu mice were purchased from SLC Inc. (Hamamatsu, Japan) and maintained in a specific pathogen-free environment with free access to food and water at the laboratory animal center of Okayama University. They were allowed to adapt to their environment for more than 1 week before beginning the experiments. The animals were housed and handled in accordance with the Okayama University Animal Research Committee Guidelines.
In vivo prostate tumor model LNCaP cells (5 Â 10 6 in 50 ml Hanks' balanced salt solution) were mixed with 50 ml Matrigel (Becton Dickinson, Bedford, MA) and subcutaneously injected into the right flank of the nude mice. In the bilateral tumor experiments, the same number of cells was inoculated into the respective flanks. The tumors in the right or both sides were permitted to grow up to 5-10 mm in diameter and then the mice were randomly assigned into the treatment groups with intratumoral injection of Ad-LacZ or OBP-301 in 100 ml buffer, or of 100 ml phosphate-buffered saline (PBS). As for the OBP-301 administration, the right-side tumors were intratumorally injected with two doses (three times administration (10 7 PFU per tumor Â 3 consecutive days), or a single administration of 10 7 PFU per tumor). The injections were targeted to the center and periphery of each mass to deliver the agent diffusely. 15 The size of the tumor was measured with vernier calipers until 20 days after each treatment. Tumor volume was calculated using the formula, 1/2 Â (the shortest diameter) 2 Â (the longest diameter).
Histology and immunohistochemistry
For the histological analysis after the OBP-301 treatments, the mice were killed and the subcutaneous tumor and liver tissues were removed, fixed by formalin and embedded in paraffin sections. The sections (5 mm) were stained with hematoxylin and eosin and were examined for cytotoxic changes. To identify the cells infected with OBP-301 in the tumor tissue, immunohistochemistry was performed using the primary antibody against adenovirus type 5 E1A (BD PharMingen, San Diego, CA) as previously described. 16 Briefly, the tumor tissue was cut, placed in the optical cutting temperature (OCT) compound and snap frozen in liquid nitrogen. The frozen sections (10 mm) were fixed with 4% paraformaldehyde in PBS for 30 min at room temperature, washed and permeabilized with PBS containing 0.1% Triton X-100. Endogenous peroxidase activity was blocked by incubation with 3% hydrogen peroxide in methanol for 10 min. The sections were incubated with primary antibody (1:50 dilution with PBS) at room temperature for 16 h and then with the Histofine Simple Stain MAX PO (Nichirei, Tokyo, Japan) for 30 min. Bound antibodies were then detected using diaminobenzidine tetrahydrochloride as the substrate and thereafter the sections were counterstained with hematoxylin.
Statistical analysis
The data are shown as mean±s.e.m. Unpaired Student's t-test was performed for the statistical analysis between the two groups.
Differences were considered to be significant if the Pvalue was o0.05.
Results
Human telomerase reverse transcriptase expression in human prostate cancer and normal cells Human prostate cancer cell lines (LNCaP, PC3, Du145) and normal prostate cells (PrEC, PrSC) were examined for hTERT expression using a quantitative real-time reverse transcription PCR method. All of the prostate cancer cells expressed detectable levels of hTERT mRNA, although the levels varied (Figure 1a) . In contrast, the normal prostate cells were negative for hTERT expression (Figure 1a) .
In vitro cell-killing effect of OBP-301 in human prostate cancer cell lines To confirm the cancer-specific replication competence of OBP-301, we performed an in vitro transduction assay (Figures 1b and c) , although none of the normal prostatic cells indicated a detectable fluorescence (Figure 1b) . To determine whether OBP-301 infection induces selective cell killing, the LNCaP, PC3 and PrEC cells were infected with OBP-301 at the indicated MOIs. A significant reduction of LNCaP and PC3 cell viability to less than 20% was observed on day 4 after the OBP-301 treatment at MOI 10 (Figures 2a and  b) . In the PrEC cells, no statistical change was observed after each treatment (Figure 2c ).
Antitumor effect of OBP-301 treatment in in vivo human prostate cancer model
We also assessed the therapeutic efficacy of OBP-301 against the subcutaneous LNCaP tumor. First, we treated the mice intratumorally with three times OBP-301 administration (10 7 PFU per tumor Â 3 days). Macroscopically, there was no detectable tumor on treatment day 20 (Figure 3a) . We next administered OBP-301 by single administration of 10 7 PFU per tumor to confirm the antitumor effect in a lower dose. Significant tumor volume reduction was observed until day 20 in both of the OBP-301-treated groups, but not in the control groups with a single PBS or Ad-LacZ injection (Figure 3b ). To further confirm the therapeutic utility of OBP-301 gene therapy, we analyzed the antitumor effects not only in the treated tumor but also in the contralateral distant tumor. The tumor growth suppression at the OBP-301-injected side was remarkable and consistent with the result of a single-side tumor experiment (Figures 4a and b) . Notably, about a 50% reduction in tumor volume was observed in the contralateral distant tumor on day 20 (Figures 4a and  b) .
Adenoviral E1A protein expression and oncolytic degeneration in both of the side tumors
To investigate the mechanism and influence of OBP-301 action in tumors and other body tissues, the mice were killed on day 7 after treatment initiation with three times administration of PBS or OBP-301. Immunohistochemistry of the LNCaP tumors confirmed the broad expression of the adenoviral E1A protein in both the injected and other side tumors (Figure 5a ), indicating that intratumorally administered OBP-301 spread throughout the injected primary tumor and also distributed in the contralateral distant tumor. A histopathological analysis revealed massive degeneration of the tissues in the OBP-301-injected primary and the contralateral distant tumors, but not in those treated with PBS (Figure 5a ). These findings were consistent with the tumor volume reduction or growth inhibition observed after each treatment. Upon higher magnification, a widespread cytopathic effect was clearly observed in the OBP-301-injected tumors, with the disorganized cancer cells abundant in the condensed cell nuclei (Figure 5a ). In contrast, an analysis of liver sections from the mice treated with OBP-301 demonstrated no histological evidence of hepatocellular damage (Figure 5b) .
Discussion
This study demonstrated that OBP-301 possesses a strong anticancer effect against human prostate cancer cells and may be a promising tool for gene therapy. Generally, to improve the therapeutic index, there is a need for antitumor agents that selectively target only cancer cells and spare normal cells. To date, it seems that many investigators have been working to develop such cancerspecific biochemical drugs. To achieve this cancer Direct and distant antitumor effects of OBP-301 P Huang et al specificity, we have developed the replication-selective tumor-specific adenovirus, OBP-301, as a novel anticancer agent. In our in vitro study at 24 h after OBP-401 administration, no GFP-positive cells were detected in the normal prostate cells, while most of the prostate cancer cells were recognized as GFP-positive, indicating its selective replication in proliferating malignant cells where hTERT activity should be high. Next, we revealed the cancerspecific cytotoxic/oncolytic effect of OBP-301. In the cellkilling assay, the OBP-301 treatment induced significant and dose-dependent cell death in the LNCaP and PC3 cells. On the other hand, under the same conditions as the cancer cells, no cell death was recognized in the normal PrEC cells. It is evident that OBP-301 works well against prostate cancer by its selective replication ability in cancer cells. Importantly, the intratumoral three-time administration of OBP-301 significantly inhibited the growth of both the injected primary tumor and the distant other-site tumors, revealing its robust therapeutic effects in the current in vivo prostate cancer model. In both-side tumor experiments, we detected the viral DNA by PCR amplification of the adenoviral E1A sequence in the blood sample from day 7 after the intratumoral OBP-301 injection (data not shown). This result is consistent with our previous results showing adenoviral presence in the blood of the treated model mice. 9 It is conceivable that the viruses were transported to the contralateral uninjected tumor through the blood stream and then spread within the LNCaP xenograft tumor. Therefore, the strong anticancer effect with a definite cancer specificity suggests that OBP-301 could thus be an attractive agent to On the other hand, clinical advances in cancer gene therapy will probably require cooperation with more established treatments, such as chemotherapy, radiotherapy and immunotherapy, to show efficacy. One key in OBP-301 use for prostate cancer may be the combination with chemotherapy. A considerable number of patients with prostate cancer need the additional treatment following the progression of the disease. A promising chemotherapeutic agent for aggressive prostate cancer, such as androgen-independent prostate cancer, is docetaxel, which has antiprostate cancer effects in 40% of individuals with androgen-independent prostate cancer. 17 A previous study showed that OBP-401 in combination with docetaxel efficiently enhanced the antitumor efficacy in an in vivo human lung tumor model. 12 Because telomerase activity is reportedly higher in aggressive prostate cancer than in non-aggressive forms, 18 we speculate that progressive prostate cancer, such as androgen-independent prostate cancer, preferentially responds to OBP-301 treatment. These findings thus suggest that the concomitant use of docetaxel may therefore augment the effect of OBP-301 against prostate cancer.
In this study, a significant therapeutic effect of intratumoral OBP-301 treatment was achieved without either any definite toxicity or side effects in the liver. In the other experiments, we performed additional toxicological analyses in an immunocompetent C57/BL6 mouse model with subcutaneous RM9 (mouse prostate cancer cell) tumors formed on the flanks of both sides. After three intratumoral administrations of OBP-301 to the right-side tumor, we performed histological analyses in the brain, lung, heart, liver, spleen, stomach, kidney, bladder and colon. As a result, no significant change was observed in any tissue specimens between the PBS-and OBP-301-treated mice (data not shown). Notably, the clinical trial is currently ongoing using the telomeraseselective oncolytic OBP-301 in patients suffering from advanced solid cancer disease. The gene therapeutic trial may further show its clinical efficacy and yield additional safety information. As for the clinical use of OBP-301 in prostate cancer, the preliminary information obtained from our study is therefore considered to be useful for planning future phase I trials.
In conclusion, our results clearly show that OBP-301 has both in vitro and in vivo anticancer effects against human prostate cancer cells. The findings are encouraging in view of clinical applications of OBP-301 not only to primary prostate cancer lesions but also to metastatic lesions. Our findings suggest that this kind of replicationselective, oncolytic virus provides a new platform to treat a variety of human cancers.
